# Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer

> **NCT03957252** · — · ACTIVE_NOT_RECRUITING · sponsor: **Nanostics** · enrollment: 2800 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Blood test: ClarityDX Prostate

## Key facts

- **NCT ID:** NCT03957252
- **Lead sponsor:** Nanostics
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-06
- **Primary completion:** 2026-11
- **Final completion:** 2027-03
- **Target enrollment:** 2800 (ESTIMATED)
- **Last updated:** 2025-05-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03957252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03957252, "Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03957252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*